1 / 8

Aghajanian C et al. Proc ASCO 2011;Abstract LBA5007.

OCEANS: A Randomized, Double-Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-Sensitive Recurrent Epithelial Ovarian (EOC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC). Aghajanian C et al.

amanda-chen
Download Presentation

Aghajanian C et al. Proc ASCO 2011;Abstract LBA5007.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OCEANS: A Randomized, Double-Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-Sensitive Recurrent Epithelial Ovarian (EOC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC) Aghajanian C et al. Proc ASCO 2011;Abstract LBA5007.

  2. Oceans Study Schema Accrual: 484 (Closed) CG x 6-10 cycles + PL q3wk, until progression R CG x 6-10 cycles + bev q3wk, until progression C = carboplatin AUC4; G = gemcitabine 1,000 mg/m2, d1 & 8; PL = placebo; bev = bevacizumab Aghajanian C et al. Proc ASCO 2011;Abstract LBA5007.

  3. OCEANS: Patient Characteristics Aghajanian C et al. Proc ASCO 2011;Abstract LBA5007.

  4. OCEANS: Response Aghajanian C et al. Proc ASCO 2011;Abstract LBA5007.

  5. OCEANS: Progression-Free Survival Aghajanian C et al. Proc ASCO 2011;Abstract LBA5007.

  6. OCEANS: Select Adverse Events Aghajanian C et al. Proc ASCO 2011;Abstract LBA5007.

  7. Author Conclusions • Bevacizumab/carboplatin/gemcitabine followed by bevacizumab until progression provides clinically meaningful benefit compared to chemotherapy alone in recurrent OC • Improved PFS: 12.4 months vs 8.4 months; HR = 0.484 (p < 0.0001) • Improved ORR: 78% vs 57% (p < 0.0001) • Improved DOR: 10.4 months vs 7.4 months • Safety data are consistent with the profile for bevacizumab • This regimen should be considered a new option for recurrent platinum-sensitive OC Aghajanian C et al. Proc ASCO 2011;Abstract LBA5007.

  8. Investigator Commentary: Results from the OCEANS Phase III Trial The OCEANS study built in concurrent chemotherapy with bevacizumab in a population that was platinum sensitive with recurrent disease. This study did provide bevacizumab until progression as maintenance and showed a significant separation of the curves from the beginning of therapy, which continued for a long time. The hazard ratio of about 0.48 was statistically significant, and I believe that continuing with bevacizumab until progression probably maintained disease control for a longer period. What seems to be emerging is that continuing with bevacizumab until progression would make sense in patients who are at high risk of having recurrent disease over a short period. Amit M Oza, MD The data in ovarian cancer have continued to accumulate in a positive way. The OCEANS study showed a substantial advantage in time to progression in the patients who had received bevacizumab with carboplatin and gemcitabine, as opposed to the carboplatin, gemcitabine and placebo group, and this seems to be a positive option. David R Spriggs, MD

More Related